bit.bio featured in TechRound
In this TechRound article, our CEO, Dr Emma Pepperell, joins leading industry experts to discuss why reliability has become the most valuable and urgent quality in UK HealthTech today.
As the sector shifts from an "innovation-first" to an "evidence-first" approach, the demand for consistent, dependable solutions has never been higher. For bit.bio, building a reliable healthcare ecosystem starts at the very beginning during drug discovery and development. We are designing tools that directly address consistency issues in preclinical drug development and toxicity testing. Reliable healthcare does not just start in the clinic; consistency must be built into every stage of the medical process, starting with early-stage drug discovery.
"One of the greatest opportunities in UK healthcare is improving the quality and reproducibility of the biological models that underpin research and drug discovery. More reliable healthcare solutions begin with more reliable science. By programming human cells with high consistency and manufacturing them at scale, we aim to provide researchers with human-relevant models that can reduce experimental variability and generate more dependable data."
Emma Pepperell, PhD
CEO, bit.bio
Read the full article
